At a time when Covid infections are on the rise again in France (894 cases per 100,000 inhabitants in one week, according to the latest figures from Public Health France), the first announcements about the performance of the Omicron-adapted RNA vaccines are quite numerous. encouraging. But the meteoric rise of the BA.4 and BA.5 subtypes, which are responsible for most of the current epidemic waves, and the deadlock in the epidemic are already calling into question their relevance.
The pharmaceutical groups behind the RNA vaccines, Pfizer/BioNTech and Moderna, have each reported significant improvements in the efficacy of their new versions adapted to the Omicron version, which is still being tested. The Pfizer/BioNTech duo is developing two products, one monovalent, specifically targeting Omicron BA.1, which hit France earlier this year. Current Phase 2/3 trials in patients 56 and older show it can increase…
Source: Le Figaro
